TaiMed Biologics Inc. (4147.TWO)

87.90 +1.20 (+1.38%) At close: 01:23PM CST

TaiMed Biologics Inc.

No. 607, Ruiguang Road
3rd Floor Neihu District
Taipei 11492
Taiwan
886 2 2658 0058
https://www.taimedbiologics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Chin-Ming Chang Ph.D.	President & CEO	N/A	N/A	N/A
Dr. David D. Ho M.D.	Scientific Co-Founder, Chief Scientific Advisor and Board Director	N/A	N/A	1953
Dr. Ing-Wen Tsai Ph.D.	Co-Founder	N/A	N/A	N/A
Dr. Lan-Bo Chen Ph.D.	Co-Founder	N/A	N/A	N/A
Mr. Jack Chen	CFO & Chief of Corporate Governance	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.

Description

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. It develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-365/TMB-380, a neutralizing HIV-1 antibody. The company was incorporated in 2007 and is headquartered in Taipei, Taiwan.

Corporate governance

TaiMed Biologics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.